U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07208136) titled 'A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors' on Sept. 28.
Brief Summary: This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: JMKX005425
JMKX005425 administered orally.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jemincare
Disc...